BRIEF-Psivida Corp says first Phase 3 trial of Medidur continued to meet primary endpoint

* First phase 3 trial of medidur for treatment of posterior uveitis continued to meet its primary endpoint Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)